Ongoing Clinical Trials for Adenosquamous Cell Lung Cancer
There are currently 4 ongoing clinical trials investigating new treatments for adenosquamous cell lung cancer. These studies are testing different approaches including antibody-drug conjugates, immunotherapy combinations, diagnostic breath tests, and personalized cell therapies. Trials are being conducted across multiple European countries including Belgium, Spain, Germany, France, Hungary, and Czechia.
Clinical trial locations
- Belgium
- Czechia
- France
- Germany
- Hungary
- Spain
Study of JK06 for Patients with Advanced or Metastatic Cancer
This trial is testing JK06, an antibody-drug conjugate, for patients with cancer that cannot be removed by surgery or has spread to other parts of the body. The medication is given through an intravenous infusion every three weeks.
Who can participate:
The trial is open to adults aged 18 or older who have various types of advanced cancers, including non-small cell lung cancer. Participants must have tried standard treatments or be unable to receive them. Those eligible must have a good performance status, meaning they can carry out daily activities with minimal restrictions. Women who can become pregnant must use two forms of effective birth control during the study and for 90 days after the last dose. Men with partners who can become pregnant must also use effective contraception. Patients must be willing to attend clinic visits and follow study procedures. If cancer has spread to the brain, it must have been treated and stable for at least 14 days.
Who cannot participate:
The trial excludes patients who have received other cancer treatments recently, those with certain health conditions that could interfere with the study, and anyone who is pregnant or breastfeeding. People with allergies to the study medication or its ingredients, those unable to follow study procedures, and individuals participating in another clinical trial at the same time cannot join. Patients with uncontrolled infections, certain heart conditions, recent surgery, or a history of substance abuse may also be excluded.
Study focus:
The trial aims to determine the safety and tolerability of JK06 and find the most effective dose for future studies. JK06 is designed to target and attack cancer cells specifically by combining an antibody with a cancer-fighting drug. The study will monitor patients closely for side effects and changes in their condition throughout the treatment period, which is expected to continue until 2028.
Study on Atezolizumab, Carboplatin, and Etoposide for Adults with Advanced Large-Cell Neuroendocrine Lung Cancer
This trial is investigating a combination of immunotherapy and chemotherapy for a specific type of lung cancer called large-cell neuroendocrine carcinoma. The treatments are delivered directly into the bloodstream through intravenous infusion.
Who can participate:
Eligible participants must be at least 18 years old and have locally advanced or metastatic large-cell neuroendocrine carcinoma without options for curative treatment. If the cancer has mixed types, this type should make up at least 50% of the tumor. Patients must not have received previous systemic therapy, although those who had curative treatment and experienced cancer return at least 6 months later can participate. Participants must plan to receive treatment with Carboplatin or Cisplatin and Etoposide. An ECOG performance status of 0 to 2 is required, meaning patients should be able to perform daily activities to some degree. The cancer must be measurable according to specific criteria. Adequate organ function is necessary, including acceptable levels of liver enzymes, bilirubin, creatinine, neutrophils, and platelets.
Who cannot participate:
Patients who have received any cancer treatment within the last 4 weeks cannot join. The trial also excludes those with severe allergic reactions to the study drugs, active infections requiring treatment, or other serious medical conditions. Pregnant or breastfeeding women are not eligible. Those who participated in another clinical trial within the last 4 weeks or have a history of another type of cancer unless in remission for at least 5 years are excluded. Patients with brain metastases unless treated and stable, autoimmune diseases unless stable, or a history of drug or alcohol abuse within the last 12 months cannot participate.
Study focus:
The trial is evaluating how well Atezolizumab, an immunotherapy that helps the immune system fight cancer, works together with platinum-based chemotherapy drugs (Carboplatin or Cisplatin) and Etoposide. Atezolizumab blocks a protein that helps cancer cells hide from the immune system, allowing the body to better attack the cancer. The study will monitor how patients respond to treatment, how long they survive, and any side effects they experience. The trial is expected to continue until January 2029.
Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings
This trial is testing a new diagnostic method called the OWL-EVO1 Breath Biopsy test, which aims to help identify lung cancer by analyzing breath samples. The test uses a solution called D5-ethyl-beta-D-glucuronide given through intravenous infusion.
Who can participate:
Eligible participants must be between 45 and 85 years old and able to understand the study and provide informed consent. They must have a BMI between 16 and less than 40, which is a measure calculated from height and weight. Participants must have had a CT scan of the chest area within the last 6 months.
Who cannot participate:
The trial excludes individuals who are not eligible for lung cancer screening based on low dose CT scans. Those without suspicious findings on a CT scan that might indicate lung cancer cannot participate. People whose symptoms do not include lung cancer as a possible diagnosis are also excluded.
Study focus:
The trial is assessing how accurately the OWL-EVO1 test can differentiate between people who have lung cancer and those who do not. The test works by analyzing volatile organic compounds in the breath that may indicate cancer presence. Breath samples are collected at various times, and participants are monitored for any adverse events. The goal is to determine if this non-invasive test can be a reliable tool for earlier and more accurate lung cancer detection. The study was estimated to conclude in August 2024.
Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer
This trial is exploring a personalized cell therapy called ATL001, which uses specially designed immune cells to target cancer. The study examines ATL001 both alone and in combination with pembrolizumab, an immunotherapy medication already used in cancer treatment.
Who can participate:
Participants must be between 18 and 75 years old with a life expectancy of at least 6 months. They must have advanced non-small cell lung cancer that cannot be removed by surgery or has spread, and the cancer must have worsened after standard treatments or the patient cannot receive standard treatments due to side effects. The cancer must be measurable according to specific guidelines. Patients must be considered well enough by their doctor to receive treatment, based on a performance status scale of ECOG 0-1. Before receiving the study treatment, participants must have been treated with a PD-1/PD-L1 inhibitor medication and experienced disease progression or stable disease after at least four doses. Female patients in certain groups must agree to use effective birth control during treatment and for at least 4 months after, with pregnancy tests before each session. Participants must have adequate organ function shown by blood test results and be medically fit to undergo all study procedures, including blood and tissue collection. Both female and male patients must agree to use appropriate birth control methods for specified periods after treatment.
Who cannot participate:
Patients with other types of cancer besides non-small cell lung cancer cannot participate. Those outside the specified age range, unable to follow study procedures, or with certain medical conditions that might interfere with the study are excluded. Patients taking medications that might interfere with the study, those who are pregnant or breastfeeding, and those who participated in another recent clinical trial may not be eligible. People with a history of allergic reactions to the study drugs are also excluded.
Study focus:
The trial aims to assess the safety and tolerability of ATL001, which uses special T cells designed to recognize and attack cancer cells in patients with advanced non-small cell lung cancer. ATL001 is administered as an infusion after a preparation process called lymphodepletion, which involves medications to prepare the body for treatment. In some cases, ATL001 is combined with pembrolizumab, which works by blocking a protein called PD-1 that prevents the immune system from attacking cancer cells. The study will monitor patients’ responses through regular assessments, including imaging studies to evaluate changes in tumor size. The trial is expected to conclude by July 2027.
Summary
These four ongoing trials represent diverse approaches to treating and diagnosing adenosquamous cell lung cancer and related lung cancers. The studies span multiple European countries, with Germany and Spain each hosting two trials, while Belgium, France, Hungary, and Czechia each host one study.
The trials focus on different treatment strategies. Two studies investigate immunotherapy combinations, with one testing atezolizumab with standard chemotherapy and another examining personalized cell therapy ATL001 with pembrolizumab. One trial explores JK06, a novel antibody-drug conjugate targeting multiple cancer types. Notably, one study takes a different approach by testing a diagnostic breath test rather than a treatment, aiming to improve early lung cancer detection.
Pembrolizumab appears in two of these trials, highlighting the continued interest in immunotherapy approaches for lung cancer. The studies vary in their stage of research, from early phase dose-finding trials to more advanced phase studies with established treatments. Most trials require patients to have advanced disease that has not responded to standard treatments, reflecting the need for new options for difficult-to-treat cases.
